Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1992 Jan 25;304(6821):212–216. doi: 10.1136/bmj.304.6821.212

Variability in serial CD4 counts and relation to progression of HIV-I infection to AIDS in haemophilic patients. Transfusion Safety Study Group.

L M Aledort 1, M W Hilgartner 1, M C Pike 1, G F Gjerset 1, M A Koerper 1, E Y Lian 1, J M Lusher 1, J W Mosley 1
PMCID: PMC1881487  PMID: 1346752

Abstract

OBJECTIVE--To examine the CD4 count and its near term changes relative to progression to AIDS within 30 months and to subsequent CD4 counts. DESIGN--Longitudinal clinical and laboratory study. SETTING--Haemophilia treatment centres in six large American cities. PATIENTS--555 people with congenital clotting disorders who were infected with HIV, initially without AIDS, and seen at follow up for 6-30 months in 1986-9. MAIN OUTCOME MEASURES--Absolute CD4 counts and incidence of AIDS. RESULTS--Outset CD4 count and age were independently related to progression to AIDS (p less than 0.0001 and p less than 0.005 respectively). Patients with CD4 counts of 0.30-0.49 x 10(9) cells/l had an age adjusted risk of AIDS within 30 months of only 9% that of patients with counts less than 0.20 x 10(9)/l. Children under 10 years old had only 16% of the CD4 adjusted risk of AIDS of people aged greater than or equal to 45 years. Analysis of 149 patients' CD4 counts at the beginning and end of two successive six month intervals showed an average decrease of 11% in each six months regardless of the outset count (greater than or equal to 0.20 x 10(9)/l). For individual patients the decrease in the second six month period was unaffected by the decrease in the first six month period. CONCLUSIONS--Antiviral treatment of asymptomatic people, particularly children, with CD4 counts greater than or equal to 0.3 x 10(9)/l is questionable if predicted on near term progression to AIDS. Because of individual CD4 count variability and the low rate of progression to AIDS near term declines in individual CD4 counts are a poor index for identifying people who will rapidly progress to AIDS.

Full text

PDF
212

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cuthbert R. J., Ludlam C. A., Tucker J., Steel C. M., Beatson D., Rebus S., Peutherer J. F. Five year prospective study of HIV infection in the Edinburgh haemophiliac cohort. BMJ. 1990 Oct 27;301(6758):956–961. doi: 10.1136/bmj.301.6758.956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Darby S. C., Rizza C. R., Doll R., Spooner R. J., Stratton I. M., Thakrar B. Incidence of AIDS and excess of mortality associated with HIV in haemophiliacs in the United Kingdom: report on behalf of the directors of haemophilia centres in the United Kingdom. BMJ. 1989 Apr 22;298(6680):1064–1068. doi: 10.1136/bmj.298.6680.1064. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Eyster M. E., Gail M. H., Ballard J. O., Al-Mondhiry H., Goedert J. J. Natural history of human immunodeficiency virus infections in hemophiliacs: effects of T-cell subsets, platelet counts, and age. Ann Intern Med. 1987 Jul;107(1):1–6. doi: 10.7326/0003-4819-107-1-1. [DOI] [PubMed] [Google Scholar]
  4. Fahey J. L., Taylor J. M., Detels R., Hofmann B., Melmed R., Nishanian P., Giorgi J. V. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med. 1990 Jan 18;322(3):166–172. doi: 10.1056/NEJM199001183220305. [DOI] [PubMed] [Google Scholar]
  5. Friedland G. H. Early treatment for HIV: the time has come. N Engl J Med. 1990 Apr 5;322(14):1000–1002. doi: 10.1056/NEJM199004053221409. [DOI] [PubMed] [Google Scholar]
  6. Goedert J. J., Kessler C. M., Aledort L. M., Biggar R. J., Andes W. A., White G. C., 2nd, Drummond J. E., Vaidya K., Mann D. L., Eyster M. E. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med. 1989 Oct 26;321(17):1141–1148. doi: 10.1056/NEJM198910263211701. [DOI] [PubMed] [Google Scholar]
  7. Goedert J. J. Prognostic markers for AIDS. Ann Epidemiol. 1990 Dec;1(2):129–139. doi: 10.1016/1047-2797(90)90004-c. [DOI] [PubMed] [Google Scholar]
  8. Kaplan J. E., Spira T. J., Fishbein D. B., Bozeman L. H., Pinsky P. F., Schonberger L. B. A six-year follow-up of HIV-infected homosexual men with lymphadenopathy. Evidence for an increased risk for developing AIDS after the third year of lymphadenopathy. JAMA. 1988 Nov 11;260(18):2694–2697. [PubMed] [Google Scholar]
  9. Lang W., Perkins H., Anderson R. E., Royce R., Jewell N., Winkelstein W., Jr Patterns of T lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS. J Acquir Immune Defic Syndr. 1989;2(1):63–69. [PubMed] [Google Scholar]
  10. Larder B. A., Darby G., Richman D. D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989 Mar 31;243(4899):1731–1734. doi: 10.1126/science.2467383. [DOI] [PubMed] [Google Scholar]
  11. Medley G. F., Billard L., Cox D. R., Anderson R. M. The distribution of the incubation period for the acquired immunodeficiency syndrome (AIDS). Proc R Soc Lond B Biol Sci. 1988 Apr 22;233(1272):367–377. doi: 10.1098/rspb.1988.0026. [DOI] [PubMed] [Google Scholar]
  12. Moss A. R., Bacchetti P., Osmond D., Krampf W., Chaisson R. E., Stites D., Wilber J., Allain J. P., Carlson J. Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort. Br Med J (Clin Res Ed) 1988 Mar 12;296(6624):745–750. doi: 10.1136/bmj.296.6624.745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Moss A. R. Laboratory markers as potential surrogates for clinical outcomes in AIDS trials. J Acquir Immune Defic Syndr. 1990;3 (Suppl 2):S69–S71. [PubMed] [Google Scholar]
  14. Osmond D. H., Shiboski S., Bacchetti P., Winger E. E., Moss A. R. Immune activation markers and AIDS prognosis. AIDS. 1991 May;5(5):505–511. doi: 10.1097/00002030-199105000-00005. [DOI] [PubMed] [Google Scholar]
  15. Parker J. W., Adelsberg B., Azen S. P., Boone D., Fletcher M. A., Gjerset G. F., Hassett J., Kaplan J., Niland J. C., Odom-Maryon T. Leukocyte immunophenotyping by flow cytometry in a multisite study: standardization, quality control, and normal values in the Transfusion Safety Study. The Transfusion Safety Study Group. Clin Immunol Immunopathol. 1990 May;55(2):187–220. doi: 10.1016/0090-1229(90)90097-a. [DOI] [PubMed] [Google Scholar]
  16. Phillips A. N., Lee C. A., Elford J., Janossy G., Timms A., Bofill M., Kernoff P. B. Serial CD4 lymphocyte counts and development of AIDS. Lancet. 1991 Feb 16;337(8738):389–392. doi: 10.1016/0140-6736(91)91166-r. [DOI] [PubMed] [Google Scholar]
  17. Ragni M. V., Kingsley L. A. Cumulative risk for AIDS and other HIV outcomes in a cohort of hemophiliacs in western Pennsylvania. J Acquir Immune Defic Syndr. 1990;3(7):708–713. [PubMed] [Google Scholar]
  18. Richman D. D., Fischl M. A., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Hirsch M. S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):192–197. doi: 10.1056/NEJM198707233170402. [DOI] [PubMed] [Google Scholar]
  19. Simmonds P., Lainson F. A., Cuthbert R., Steel C. M., Peutherer J. F., Ludlam C. A. HIV antigen and antibody detection: variable responses to infection in the Edinburgh haemophiliac cohort. Br Med J (Clin Res Ed) 1988 Feb 27;296(6622):593–598. doi: 10.1136/bmj.296.6622.593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Thomas D. G., Breslow N., Gart J. J. Trend and homogeneity analyses of proportions and life table data. Comput Biomed Res. 1977 Aug;10(4):373–381. doi: 10.1016/0010-4809(77)90006-4. [DOI] [PubMed] [Google Scholar]
  21. Vermund S. H., Hoth D. F. How can epidemiology assist in guiding interventions for the acquired immunodeficiency syndrome/human immunodeficiency virus? Ann Epidemiol. 1990 Dec;1(2):141–155. doi: 10.1016/1047-2797(90)90005-d. [DOI] [PubMed] [Google Scholar]
  22. Volberding P. A., Lagakos S. W., Koch M. A., Pettinelli C., Myers M. W., Booth D. K., Balfour H. H., Jr, Reichman R. C., Bartlett J. A., Hirsch M. S. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med. 1990 Apr 5;322(14):941–949. doi: 10.1056/NEJM199004053221401. [DOI] [PubMed] [Google Scholar]
  23. Zidovudine in asymptomatic HIV infection. N Engl J Med. 1990 Sep 13;323(11):754–756. doi: 10.1056/NEJM199009133231112. [DOI] [PubMed] [Google Scholar]
  24. de Truchis P., Salmon D., Matheron S., Jelasko P., Rozenbaum W., Leport C. Half-dose zidovudine. Lancet. 1991 May 4;337(8749):1109–1109. doi: 10.1016/0140-6736(91)91766-n. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES